Clinical Trials Logo

Clinical Trial Summary

This is a single arm, open-label, single-center, phase I/II study to determine the safety and efficacy of CD19 CAR-T( ssCART-19) combined with feeding T cells (FTCs) as consolidation therapy in patients diagnosed with de novo Philadelphia chromosome positive CD19+ B-ALL. The study will contain the following sequential phases: screening, lymphocyte apheresis, induction and consolidation chemotherapies combined with tyrosine kinase inhibitors. Once in complete response, patients will receive four cycles of ssCART-19s, namely one cycle of ssCART-19 infusion followed by another three cycles of ssCART-19 and FTC infusion. The role of FTCs is to mimic leukemia cells. Therefore, they are expected to stimulate in vivo expansion and persistence of ssCART-19. Considering the limited number of lymphocytes obtained by a single apheresis from patients and cost-efficacy, in addition to safety, we will explore the range of biologically active doses of FTCs in a phase I study. Based on preclinical data, FTCs stimulation of ssCART-19 at a ratio of 1:1 could achieve the best activation response, so 5×106/kg dosage of FTCs was set as the initial dosage in the study, and lower dose was also evaluated. In this study, FTCs will be administered at the dose of 5×106/kg, 3.25×106/kg or 2×106/kg two hours after ssCART-19 infusion on day 1 and once again administered at the same dose on day 8. After ssCART-19 and FTCs infusion, efficacy will be assessed by detecting molecular response for 6 months, PFS and OS will be followed up for 2 years. In phase II, we will expand the study at optimal biological doses of FTCs, and further evaluate the efficacy and safety of the innovative combination therapy of CD19 CAR-T and FTCs.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03984968
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Sheng-Li Xue, M.D.
Phone +86 512 67781139
Email slxue@suda.edu.cn
Status Recruiting
Phase Phase 1/Phase 2
Start date January 1, 2018
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05059847 - Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia Adults N/A
Active, not recruiting NCT03709719 - Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia Phase 2
Active, not recruiting NCT04545333 - The clonoSEQ® Watch Registry
Completed NCT02975687 - CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia Phase 1
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT06462365 - Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) Phase 1